Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients.
BACKGROUND
Uncomplicated skin and skin structure infections (uSSSI) are commonly encountered community-acquired infections and are typically confined to the superficial layers of the skin. Hence, they seldom lead to the destruction of skin structures.


OBJECTIVE
To evaluate the efficacy and tolerability of cefditoren pivoxil in uSSSI in Indian patients.


METHODS
One hundred and seventy-eight patients diagnosed with uncomplicated SSSI were enrolled in this randomized, comparative, multicentric study. Patients received either cefditoren pivoxil or cefdinir for ten days. Efficacy was assessed both clinically and microbiologically. Safety evaluation consisted of reporting of type, frequency, severity, and causal relationship of adverse events.


RESULTS
One hundred and fifty-one patients completed the study. Clinical and bacteriological efficacy of cefditoren pivoxil was comparable to that of cefdinir in the treatment of uSSSI. One hundred and five patients were eligible for per protocol (PP) analysis of bacteriological outcome and clinical efficacy. Clinical cure or improvement was achieved in 98.00% patients treated with cefditoren pivoxil and 98.18% patients treated with cefdinir. In the modified Intent to Treat (mITT) patient population, clinical cure or improvement was recorded in 97.33% patients treated with cefditoren pivoxil and 96.20% patients treated with cefdinir. Microbiological eradication (or presumed eradication) was recorded in 88.00% patients treated with cefditoren pivoxil and 94.55% patients treated with cefdinir. The above differences in the outcome rates between the two drugs were not statistically significant. Six adverse events (AEs) (two in cefditoren group and four in cefdinir group) were reported in this study.


CONCLUSIONS
Cefditoren pivoxil 200 mg b.i.d. was effective and well tolerated in the treatment of uSSSI.
Manaktala
Charu
C
Medical Affairs and Clinical Research, Ranbaxy Laboratories Ltd, 77-B, IFFCO Road, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana, India. charu.manaktala@ranbaxy.com
Singh
Amit Kumar
AK
Verma
Manish
M
Sachdeva
Asheesh
A
Sharma
Himanshu
H
Roy
Arjun
A
Jalali
R K
RK
Gowrishankar
R
R
Kumar
A
A
Kumar
A Sainath
AS
Jayaraman
A M
AM
Swarnkar
B
B
Srinivas
C R
CR
Nayak
Chitra
C
Duttaroy
D
D
Umrigar
D
D
Jesudanam
Madhuri
M
Maheshwari
N
N
Shetty
P
P
Singh
R P
RP
Ghate
S
S
Sacchidanand
S
S
Tolat
S
S
Bhoira
Salman
S
Marfatia
Y
Y